Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review

Review suggests that glucagon-like peptide-1 receptor agonists are safe, well tolerated, and improve cardiovascular outcomes, largely independent of their antihyperglycaemic properties, but they remain underused by cardiologists.

JAMA Cardiology